SCHEMBL7203447

SCHEMBL7203447

NCCCC(NC(F)Cl)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.44
RNPEP Q9H4A4 1/20 0.41
CPB2 Q96IY4 3/20 0.40
GSR P00390 1/20 0.38
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
GGT1 P19440 1/20 0.35
SLC6A5 Q9Y345 1/20 0.35
ODC1 P11926 1/20 0.34
GNPAT O15228 1/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
GABRR1 P24046 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7603037 1.00 FOLH1 (0.44) FOLH1RNPEPCPB2GSRMMP2
SCHEMBL7198450 0.95 FOLH1 (0.50) FOLH1RNPEPCPB2GSRMMP2
SCHEMBL8734 0.85 FOLH1 (0.46) FOLH1RNPEPCPB2GSRMMP2
SCHEMBL8735 0.85 FOLH1 (0.46) FOLH1RNPEPCPB2GSRMMP2
SCHEMBL10436332 0.85 FOLH1 (0.46) FOLH1RNPEPCPB2GSRMMP2
SCHEMBL2873029 0.85 FOLH1 (0.46) FOLH1RNPEPCPB2GSRMMP2
SCHEMBL10436330 0.85 FOLH1 (0.46) FOLH1RNPEPCPB2GSRMMP2
Hydrochloric Acid SCHEMBL1560135 0.83 FOLH1 (0.45) FOLH1RNPEPCPB2GSRMMP2
Hydrochloric Acid SCHEMBL1560136 0.83 FOLH1 (0.45) FOLH1RNPEPCPB2GSRMMP2
Hydrochloric Acid SCHEMBL21933053 0.81 FOLH1 (0.44) FOLH1RNPEPCPB2GSRMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6602910-B2 Treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine ILEX ONCOLOGY, INC. 2003-08-05 US disclosed
EP-1261326-A1 D-ENANTIOMER OF DFMO AND METHODS OF USE THEREFOR FOR TREATING CANCER Ilex Oncology, Inc. (US) 2002-12-04 EP disclosed
US-20020045663-A1 D-enantiomer of DFMO and methods of use therefor ILEX ONCOLOGY, INC. (US) 2002-04-18 US disclosed
WO-2001068076-A2 D-ENANTIOMER OF DFMO AND METHODS OF USE THEREOF FOR TREATING CANCER ILEX ONCOLOGY, INC. (US) 2001-09-20 WO disclosed
US-6008386-A ALPHA-AMINO ACIDS BEARING AN OXIRANE RING ON THE ALPHA CARBON IN PLACE OF THE ALPHA-PROTON; IRREVERSIBLE INHIBITORS FOR AMINO ACID DECARBOXYLASES BOARD OF REGENTS UNIVERSITY OF NEBRASKA-LINCOLN (US) 1999-12-28 US disclosed
US-5705660-A Method for the synthesis of α-oxiranyl amino acids BOARD OF REGENTS, UNIVERSITY OF NEBRASKA-LINCOLN 1998-01-06 US disclosed
EP-0326766-A1 5-Substituted ornithine derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1989-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020045663-A1 D-enantiomer of DFMO and methods of use therefor DHODH, DDT, HADHB FOLH1 39/4885RNPEP 1764/4885CPB2 2478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.